Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma

Cancer Biology and Therapy

Volumn 6, Issue 2, 2007, Pages 246-252

  Cao, Xiaobo ^b   Rodarte, Charles ^b   Zhang, Lidong ^b   Morgan, Clinton D ^b   Littlejohn, James ^b   Smythe, W Roy ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

2 methoxy antimycin A3; Animal model; Apoptosis; Bcl xL; BH3 peptide; Chemotherapy; Mesothelioma; Mitochondrial membrane potential; Small molecule inhibitor; Synergy

Indexed keywords

2 METHOXY ANTIMYCIN A3; ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; ANTIMYCIN A1; BCL2L1 PROTEIN, HUMAN; DRUG DERIVATIVE; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL MEMBRANE POTENTIAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MESOTHELIOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL LINE; CLINICAL TRIAL; DRUG EFFECT; IN VITRO STUDY; PLEURA TUMOR; PROTO ONCOGENE;

ANTIMYCIN A; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; GENES, BCL-2; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 34247336873     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.2.3626     Document Type: Article

References (21)

1. Smythe WR. Current therapy for malignant mesothelioma. Curr Oncol Rep 2002; 4:305-13.
2. Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 2001; 8:547-54.
3. Wu S, Zhu H, Gu J, Zhang L, Teraishi F, Davis JJ, Jacob DA, Fang B. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol. Cancer Res 2004; 64:1110-3.
4. Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS, Fesik SW, Fill M, Thompson CB. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999; 18:632-43.
5. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60:6101-10.
6. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 2004; 3:545-50.
7. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, Cao X, Daniel J, Smythe WR, Fang B. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005; 4:451-6.
8. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5:876-85.
9. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3:173-82.
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81.
11. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery DM. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3:183-91.
12. Zhao L, Wientjes MG, Au JLS. Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994-8004.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
14. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001; 7:2887-97.
15. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. A Phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:3854-61.
16. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res 1996; 56:1621-8.
17. Kim R, Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004; 101:2491-502.
18. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G. Trastuzumab downregulates bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2gene-amplified breast cancer cells. Clin Cancer Res 2004; 10:7747-56.
19. Manion MK, O'Neill JW, Giedt CD, Kim KM, Zhang KYZ, Hockenbery DM. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem 2004; 279:2159-65.
20. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DCS. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19:1294-305.
21. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DCS. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005; 17:393-403.